Search results
PTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug
Zacks via Yahoo Finance· 3 weeks agoPTC Therapeutics (PTCT) gains 21% on May 20 after the EC decided against adopting the negative CHMP...
PTC Duchenne drug approval set to be revoked in Europe
BioPharma Dive via Yahoo Finance· 4 months agoEuropean authorities are set to rescind the approval of a Duchenne muscular dystrophy drug that’s...
European Commission, in ‘unprecedented’ move, declines to revoke approval of PTC Duchenne drug
BioPharma Dive via Yahoo Finance· 3 weeks agoRather than endorse the recommendation of the EMA, the commission called for a new review for...
PTC Therapeutics Stock Soars As Its Biggest Drug 'Lives To Fight Another Day'
Investor's Business Daily· 3 weeks agoPTC stock hit a nine-month high Monday after the European Commission decided against pulling its...
PTC Therapeutics (PTCT) Up on Positive Regulatory Updates
Zacks via Yahoo Finance· 3 months agoPTC Therapeutics (PTCT) submits BLA for gene therapy Upstaza to the FDA and announces plans to...
PTC Therapeutics Recovers From An Ugly Fall After European Officials Reject DMD Drug
Investor's Business Daily· 4 months agoPTC stock recovered its steep losses Friday after European regulators voted to withdraw the biotech...
Biotech Crashes 30% After European Regulators Yank Approval For Muscle Disease Drug
Investor's Business Daily· 9 months agoEuropean regulators voted against fully approving a Duchenne muscular dystrophy treatment from PTC...
PTC Therapeutics (PTCT) to Cut 25% Jobs by January 2024
Zacks via Yahoo Finance· 8 months agoPTC Therapeutics (PTCT) will reduce its workforce in accordance with its strategic prioritization...
PTC Stock Has Gained 41% This Week Alone, And It's Still Sprinting
Investor's Business Daily· 2 years agoShares of PTC stock on Thursday continued a seven-day run —including a 41% sprint this week — on...
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?
Motley Fool via Yahoo Finance· 4 months agoIn biotech, it's often difficult to tell whether bad news for one company will also be bad news for...